News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Insmed Incorporated to Discuss Litigation Settlement with Tercica, Inc.
March 7, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
RICHMOND, Va.--(BUSINESS WIRE)--Insmed (NASDAQ:INSM) announced that it will host a conference call on Wednesday, March 7 at 11:00 a.m. (ET) to discuss the litigation settlement with Genentech and Tercica, and other business details.
Twitter
LinkedIn
Facebook
Email
Print
Events
Legal
Insmed Incorporated
MORE ON THIS TOPIC
Podcast
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
October 28, 2026
·
1 min read
·
Jef Akst
Pancreatic cancer
EMSO 2026: Incyte a ‘firm contender’ in G12D pancreatic cancer race as early candidate shines
October 27, 2026
·
3 min read
·
Michael Gibney
Cancer
ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer
October 26, 2026
·
4 min read
·
Heather McKenzie
Prostate cancer
ESMO 2026: J&J delivers ‘immaculate’ early data for prostate cancer drug from Halda
October 26, 2026
·
2 min read
·
Tristan Manalac
